KKR, Ambersand Capital in joint bid for Oxford Immunotec: sources

Business News


FILE PHOTO: Trading information for KKR & Co is displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York, U.S., August 23, 2018. REUTERS/Brendan McDermid

(Reuters) – A consortium of private equity firms KKR & Co Inc (KKR.N) and Ampersand Capital Partners has approached Oxford Immunotec Global Plc (OXFD.O), a medical diagnostics company that develops tests to identify tuberculosis, with a $400 million acquisition offer, people familiar with the matter said on Thursday.

The offer is preliminary and was submitted to Oxford Immunotec in the last few days, the sources said. It comes after the company explored a potential sale to large healthcare peers over the course of the last year, but failed to agree on terms, the sources added.

You Might Like

KKR and Ampersand Capital have proposed to acquire Oxford Immunotec for around $15 per share in cash, subject to due diligence, the sources said. There is no certainty that the offer will lead to a deal, the sources added.

The sources asked not to be identified because the matter is confidential. Oxford Immunotec, KKR and Ambersand did not immediately respond to requests for comment.

Oxford Immunotec sells its tuberculosis test kits and associated accessories to laboratories that perform the testing themselves. It also has a clinical testing laboratory in Britain where it performs the tests on samples sent in by clients.

Its customers include independent laboratories, large hospital systems and public and private institutions.

Oxford Immunities so-called T-SPOT.TB test measures antigen-specific T cells indicative of a tuberculosis infection. About 23% of the world’s population, or about 1.7 billion people, are infected with the bacterium that causes tuberculosis, according to the World Health Organization.

Oxford Immunotec listed on the Nasdaq in 2013. Its shares ended trading on Thursday at $12.96. In 2018, the company sold its laboratory services business to Quest Diagnostics Inc (DGX.N) for gross proceeds of $170 million in cash.

Last month, Oxford Immunotec released a test for T cells to be used by researchers studying immunity to COVID-19.

Reporting by Greg Roumeliotis in New York; Editing by David Gregorio


Read the Original Article Here

Articles You May Like

‘It’s Embarrassing,’ ABC Climate Zealots Demand Biden Move Even Further Left
Over 200,000 Illegal Aliens Flew to US in Past Year, Immigration Watchdog Reports
Zelenskyy’s concerns with US run deeper than just a slow delivery of weapons
Home sales stick near recent lows in August, but prices continue to climb
Damage Control: The View Skips Bribery Indictment of Democrat Menendez

Leave a Reply

Your email address will not be published. Required fields are marked *